SILVERTHORNE, Colo.–(BUSINESS WIRE)–Indication BioScience, an early-stage pharmaceutical improvement firm centered on figuring out, growing, and commercializing progressive therapies to handle unmet wants in cardiovascular well being, at the moment introduced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent US10835501B2, which pertains to pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the therapy of hypercholesterolemia and atherosclerosis.
According to the CDC, roughly 28% of Americans over forty years of age are prescribed a statin for hypercholesterolemia. Current statin therapies are related to antagonistic results together with myalgia. In US scientific practices, roughly 45% of sufferers discontinue statin use after 6 months use attributable to antagonistic results.
Cannabinoids are a various class of small molecules that work together on the g-coupled receptor subtypes CB1 and CB2. Cannabinoids are mostly related to the hashish plant, nevertheless now could also be produced utilizing conventional small molecule synthesis strategies. Findings recommend that cannabinoids akin to Cannabidiol together with statins lower the antagonistic results of statin medicine whereas rising efficacy in treating heart problems akin to hypercholesterolemia.
“We are extremely pleased to have been granted the first patent for our portfolio of cannabinoid-statin combination therapies. This issuance is a first step in the development of our lead drug candidate, the atorvastatin+cannabidiol combination therapy Atorva+. The Atorva+ concept began with observations in the legal medicinal cannabis community, and led us to an understanding of the potential of the combination in the treatment of cardiovascular disease,” mentioned CEO Mathew Sherwood. “
“The clinical implications and potential health outcomes of this combination may be revolutionary in achieving a cost effective alternative for hard to treat lipid abnormalities and improved long term cardiovascular health. Our ongoing pre-clinical research studies are designed to confirm optimal dosing combinations to achieve appropriate outcomes in a global marketplace. The economic advantages are significant and we look for appropriate partners to facilitate our growth,” mentioned President Jim Smeeding R.Ph., MBA.